T cells, a component of the adaptive immune system, are involved in autoimmune diseases. Accumulating evidence points to dysregulated T cell metabolism in autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients. In the July issue of Cell Metabolism, Jenkins and colleagues investigated the effects of SGLT2 inhibitors on T cell function by assessing the levels of inflammatory molecules released, changes in proliferation, gene expression, and metabolism of T cells.